Aurora Cannabis (TSE:ACB) had its price target cut by equities researchers at Canaccord Genuity from C$3.00 to C$2.25 in a research report issued to clients and investors on Friday, BayStreet.CA reports. Canaccord Genuity’s target price would suggest a potential upside of 9.22% from the company’s previous close.
Several other research analysts also recently commented on ACB. Jefferies Financial Group downgraded shares of Aurora Cannabis from a “buy” rating to a “hold” rating and cut their price objective for the stock from C$7.00 to C$3.00 in a report on Tuesday, December 24th. CIBC lowered their target price on shares of Aurora Cannabis from C$5.00 to C$2.50 in a report on Monday. Pi Financial downgraded Aurora Cannabis from a “buy” rating to a “neutral” rating and dropped their target price for the stock from C$6.00 to C$2.00 in a research report on Monday. Cantor Fitzgerald upgraded Aurora Cannabis from a “neutral” rating to an “overweight” rating in a research report on Friday, November 15th. Finally, Eight Capital lowered Aurora Cannabis from a “buy” rating to a “neutral” rating and cut their price target for the stock from C$6.00 to C$2.00 in a report on Friday, February 7th. One research analyst has rated the stock with a sell rating, seven have given a hold rating and five have assigned a buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average target price of C$6.05.
TSE:ACB traded up C$0.10 on Friday, reaching C$2.06. 11,339,353 shares of the company’s stock were exchanged, compared to its average volume of 9,133,689. The firm has a market cap of $2.53 billion and a price-to-earnings ratio of -5.63. The company has a debt-to-equity ratio of 17.82, a current ratio of 1.27 and a quick ratio of 0.63. The stock has a fifty day simple moving average of C$2.50 and a 200-day simple moving average of C$4.89. Aurora Cannabis has a 52 week low of C$1.90 and a 52 week high of C$13.67.
Aurora Cannabis (TSE:ACB) last posted its quarterly earnings results on Thursday, November 14th. The company reported C$0.01 earnings per share (EPS) for the quarter, beating the consensus estimate of C($0.04) by C$0.05. The business had revenue of C$75.25 million during the quarter, compared to the consensus estimate of C$95.87 million. As a group, sell-side analysts predict that Aurora Cannabis will post -0.15 EPS for the current year.
About Aurora Cannabis
Aurora Cannabis Inc produces and distributes medical cannabis products. It is vertically integrated and horizontally diversified across various segments of the cannabis value chain, from facility engineering and design to cannabis breeding, genetics research, production, derivatives, high value-add product development, home cultivation, wholesale, and retail distribution.
Recommended Story: How can you know how many shares are floating?
Receive News & Ratings for Aurora Cannabis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurora Cannabis and related companies with MarketBeat.com's FREE daily email newsletter.